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EXPANDING THE WHIPPLE ACCELERATED
RECOVERY PATHWAY (WARP) TO ALL
PATIENTS UNDERGOING
PANCREATICODUODENECTOMY (PD)
Ava Torjani, Clifford Yudkoff**, Taylor R. Kavanagh**, Wilbur Bowne*, Geoffrey
W. Krampitz; Hamza Rshaidat; Cyrus J. Sholevar, Alexandra C. Leto; William
Preston; Elwin Tham; Mandeep Shergill; Shawnna Cannaday; Theresa P.
Yeo; Harish Lavu; Charles J. Yeo

Introduction
•

Enhanced recovery after surgery refers to an optimization of preoperative, intraoperative,
and postoperative care via a multidisciplinary team and multi-modal approach
– E.g. Earlier removal of NG tube, reduced length of stay (LOS)

•

A reduced LOS reduces time to adjuvant therapy (TTAT), which has been shown to improve
patient outcomes and cost savings per patient ($3010 for colorectal and $7020 for pancreas
surgery)

•

However, readmission rate (RR) were found to be higher, particularly in patients with renal
insufficiency, sepsis, pancreatic fistula, and delayed gastric emptying (DGE)

•

Whipple Accelerated Recovery Pathway (WARP) trial at Jefferson aimed to reduce LOS to 5
days (traditional = 7 days) without increasing rate of post-operative complications (POC)
– RESULT: Reduced TTAT and hospital costs

Introduction
•

Although WARP patient outcomes are promising, the program is limited to
a highly selective group of patients.

•

From 2017, Jefferson began implementing the WARP pathway to all
patients (previously categorized into WARP-ineligible and WARP-eligible),
hoping to improve outcomes for a larger patient population

•

This study aimed to determine if WARP could be expanded to all patients
undergoing PD by retrospectively comparing outcomes among previously
WARP-eligible and WARP-ineligible patients.

Objectives
& Hypothesis
• Research Question
– Purpose: To determine if WARP can be expanded to all risk-level patients
– Variables/outcome measures: POC (DGE and post-operative fistula
[POP]), TTAT, patients initiating adjuvant therapy (PIAT), 30-day and 90-day
mortality
– Population: WARP-eligible vs. WARP-ineligible

• Hypothesis
– The WARP pathway can be expanded to all risk-level patients undergoing
PD

Approach & Results
•

Study design & Population
– A single-institution retrospective review of 281 patients with benign (18.1%) and malignant (81.9%)
disease who underwent PD between 2017-2020
– Patients were categorized into WARP-eligible and WARP-ineligible groups based on the WARP
inclusion criteria
•

•
•

•

Intervention
– Applying WARP to WARP-ineligible patients (162 patients, 57.7%)
Comparison group
– Applying WARP to WARP-eligible patients (119 patients, 42.3%)
– Also compared to WARP patients from original WARP trial (results not included in this presentation)
Outcome
–

•

LOS, TTAT, RR, POC (including delayed gastric emptying [DGE] and pancreatic fistula [POP], 30-day
and 90-day mortality (and many, many more)

Data source, collection, and analysis
–

•

High-risk patients were excluded à CHF, end-stage renal disease, O2-dependent COPD, hepatic cirrhosis,soft pancreatic gland
texture

Data source: EPIC, google drive (excel)

– Analysis: Univariate/multivariate logical regression analysis
Rationale for Approach
– EPIC contains all information pertaining to the outcome measures
– Univariate/multivariate analysis approach to compare ≥ 1 variables

Approach & Results
Variable

WARP-eligible (n = 119)

WARP-ineligible (n = 162)

P-value

LOS

5

6

<0.05

POC

DGE (all
grades)

23.5%

POP (all
grades)

10.2%

45.1%

5.1%

26.2%

<0.05

21.0%

<0.05
<0.05

RR

12.6%

23.5%

<0.05

Median TTAT

55 days

63 days

<0.05

Patients initiating
adjuvant therapy (PIAT)

74.0%

68.5%

<0.05

30-day mortality

2.5%

0.0%

0.04

90-day mortality

3.4%

1.2%

0.22

•

Patient parameters
– E.g. Sex, Age, BMI

•

Presurgical
parameters
– E.g. Resectable vs.
Borderline

•

Intraoperative
parameters
– E.g. Operative time,
Est. blood loss, classic
Whipple vs. PPPD

•

Pathology parameters
– E.g. PDAC, duodenal
carcinoma,
cholangiocarcinoma

Conclusions
•

Our results demonstrate lower LOS, median TTAT, PIAT, 30-day and 90-day mortality
rates in both WARP-eligible and WARP-ineligible groups
– Would have been helpful to include existing LOS, TTAT, PIAT for non-WARP patients for
comparison

•

However, there is still a significant difference in findings, especially for RR and POCs
– Opens doors to future studies focusing on ways to reduce POC and RR while keeping LOS low

•

Nevertheless, our findings are consistent with current literature that enhanced recovery
after surgery, focusing on reducing LOS along with other post-operative measures, is a
significant contributor to positive patient outcomes

Future Directions
•

Comprehensive database à Several abstracts already submitted
–

Patients with G12V/R variant of pancreatic adenocarcinoma have significant greater survival compared to
patients with G12D – Collaboration with pathology department

–

Euglycemic diabetic ketoacidosis after PD may necessitate new or increased insulin at discharge and
correlates with readmission due to postoperative pancreatic fistula.

•

Future projects
–

DGE rates at Jefferson vs. other institutions

–

Significance of neoadjuvant therapy in patient outcomes and compliance/tolerability of adjuvant therapy

–

Use of perioperative beta-blockade to reduce cardiac complications

–

Opioid reduction during hospital stay

All may contribute to explaining the discrepancies in RR and POCs in WARP-eligible and WARP-ineligible
patients
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